Cargando…
FDA Approvals of Biologics in 2022
The year 2022 witnessed the control of the COVID-19 pandemic in most countries through social and hygiene measures and also vaccination campaigns. It also saw a decrease in total approvals by the U.S. Food and Drug Administration (FDA). Nevertheless, there was no fall in the Biologics class, which w...
Autores principales: | Martins, Alexander C., Albericio, Fernando, de la Torre, Beatriz G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216111/ https://www.ncbi.nlm.nih.gov/pubmed/37239105 http://dx.doi.org/10.3390/biomedicines11051434 |
Ejemplares similares
-
The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2023) -
Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
por: Martins, Alexander C., et al.
Publicado: (2022) -
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018) -
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019) -
The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2020)